Chromosome analysis

Identification and characterization of chromosome aberrations of prognostic relevance by means of banding techniques.

Testing material
  • Bone marrow (Heparin)
Processing time

3 to 7 days

Test material

Between 5 and 10 ml of bone marrow with heparin anticoagulant are needed for chromosome analysis, as the proportion of malignant cells is usually larger than in peripheral blood, and the cells obtained from the bone marrow exhibit the highest level of proliferation activity. Cytogenetic testing should only be conducted on peripheral blood (heparin vial) if it is not possible to obtain bone marrow. Chronic lymphocytic leukemia is an exception, and peripheral blood anticoagulated with heparin is the ideal test material for chromosome analysis in this case. Given that vital cells are needed for chromosome analysis, the obtained test material should arrive at a cytogenetic laboratory within 24 hours after extraction. The cells must not be frozen and should be stored at room temperature.


Chromosome analysis requires a sufficient number of metaphases in good quality. Therefore, the bone marrow or blood cells are cultured for 24-72h depending on the cell type to be analysed and then arrested at the metaphase stage by adding colcemid. Cytokines can be added to the culture medium to stimulate the malignant cell population and increase the metaphase yield during cultivation. Swelling of the cells is induced by adding a hypotonic potassium chloride solution; they are then fixed in this state with a methanol/glacial acetic acid. The cell suspension is then dripped onto slides. It is mandatory to conduct chromosome banding in order to ensure an unequivocal identification of the individual chromosomes. The most frequently used techniques are G- (giemsa), Q- (quinacrine) and R- (reverse) banding. The various banding techniques produce light and dark bands on the chromosomes that are specific to each chromosome and that hence permit unequivocal identification of the individual chromosomes. According to international consensus, 20–25 should be fully analyzed in order to produce a reliable diagnosis (ISCN).


International System of Cytogenetic Nomenclature (ISCN)

Chromosomes are classified according to their size, the centromere location (which separates the two chromosome arms) and their characteristic banding pattern. Each chromosome has a short arm (p) and a long arm (q). Based on this banding pattern, chromosomes are divided into regions and bands that are numbered outward from the centromere to the telomere. An international cytogenetic nomenclature (ISCN: International System of Cytogenetic Nomenclature) provides an exact description of all numerical and structural aberrations in a karyotype formula. The karyotype formula first states the number of chromosomes, followed by the statement of gender chromosomes. Hence, the normal female karyotype is 46,XX, while the normal male karyotype is 46,XY.

Two types of chromosome aberration

Among the numerical chromosome aberrations are monosomy (loss of one chromosome) and trisomy (gain of one chromosome). Duplications of the entire chromosome set may also occur. Normally, cells in the body will contain a double (diploid) set of chromosomes. Triple or quadruple chromosome sets are called triploids and tetraploids.

The most frequent structural chromosome aberrations are deletions (loss of chromosome parts), translocations (exchange of chromosome parts between different chromosomes), inversions (rotation of a chromosome section by 180°) and isochromosomes (chromosomes consisting of two short or long arms, with absence of the other arm).

The karyotype formula

The karyotype formula denotes the gain of a chromosome with a “+” and the loss of a chromosome with “-”, e.g. 47,XX,+8: trisomy of chromosome 8, i.e. 45,XY,-7, describes monosomy of chromosome 7. Abbreviations are defined for chromosome aberrations at international level, e.g. “t” for translocation and “inv” for inversion: t(8;21)(q22;q22) means that a breakpoint has occurred in band q22 of chromosome 8, another one in band q22 of chromosome 21, and that translocation of the fractions has taken place between the chromosomes. The karyotype formula uses a semicolon (;) to separate chromosomes and breakpoints in different chromosomes, while breaks within a single chromosome are stated in a direct line without punctuation, e.g. inv(16)(p13q22): i.e. breaks took place in the chromosome bands p13 and q22 of the same chromosome 16, and the segment between both breakpoints was inverted by 180°. Another example: del(5)(q13q31), i.e. the breaks took place in the bands q13 and q31 of the same chromosome 5, and the region between q13 and q31 has been lost.

Clonality of chromosome aberration

Chromosome aberrations are clonal if an identical structural aberration or the gain of one chromosome in at least two metaphases or the loss of the same chromosome in at least three metaphases is observed. According to ISCN only clonal chromosome abnormalities should be reported in the karyotype formula.


Request form

Please enclose this completed examination form with your sample shipment. The form represents all diagnostic methods and analyses completely.


Request form hemoglobinopathy

Order for laboratory and molecular genetic testing for hemoglobinopathies.


Patient consent - Research projects

By providing this patient consent, you agree to the use of excess biomaterial for research purposes.


Primary sample collection manual

Detailed information on test material and shipment can be found in our primary sample collection manual.


Information for correct sampling of buccal swap and nail material

Here you will find information on the correct sampling of germline material.


FAQs - questions and answers

If you have questions about placing an order, diagnostics or reports, you will find the right answers in our FAQs on the Service site.

to our FAQs

You may also be interested in


Our goal is to provide the best leukemia diagnostics for our patients through a comprehensive set of methods, state-of-the-art equipment and continuous development.

Learn more


Do you have questions about sample submission, analyses performed or findings? Here you will find contact details, contact persons and our most frequently asked questions (FAQs).

Learn more

About us

We believe that exceptional things happen when knowledge, courage and responsibility come together. In a world that offers so many possibilities, our goal is to make the best possible leukemia diagnostics available worldwide and to all patients.

Learn more

Your contact person

»Leukemia diagnostics is becoming more comprehensive as therapy becomes more individualized.«

Prof. Dr. med. Claudia Haferlach

Executive management
Medical doctor
Department manager Diagnostics

T: +49 89 99017-400